RxSight (NASDAQ:RXST) vs. Boston Scientific (NYSE:BSX) Financial Contrast

RxSight (NASDAQ:RXST) and Boston Scientific (NYSE:BSX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares RxSight and Boston Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RxSight	-43.80%	-20.11%	-16.31%
Boston Scientific	16.62%	18.61%	10.58%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for RxSight and Boston Scientific, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	2	7	2	0	2.00
Boston Scientific	2	8	20	1	2.65

RxSight presently has a consensus target price of $6.94, indicating a potential upside of 29.07%. Boston Scientific has a consensus target price of $61.43, indicating a potential upside of 38.92%. Given Boston Scientific’s stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than RxSight.

Volatility & Risk

RxSight has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Institutional and Insider Ownership

78.8% of RxSight shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares RxSight and Boston Scientific”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48 million	1.68	-$38.94 million	($1.28)	-4.20
Boston Scientific	$20.07 billion	3.19	$2.90 billion	$2.36	18.74

Boston Scientific has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats RxSight on 13 of the 15 factors compared between the two stocks.

About RxSight

RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient’s vision. Adjustments are made with RxSight’s Light Delivery Device, which uses ultraviolet light to change the lens’s optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.

About Boston Scientific

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.